TITLE

Does dutasteride reduce perioperative blood loss and postoperative complications after transurethral resection of the prostate?

AUTHOR(S)
Shanmugasundaram, R.; Singh, J. Chandra; Kekre, Nitin S.
PUB. DATE
July 2007
SOURCE
Indian Journal of Urology;Jul-Sep2007, Vol. 23 Issue 3, p334
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The primary objective of this multicentric prospective randomized trial[1] was to determine whether pretreatment with dutasteride, a dual 5α-reductase inhibitor (5ARI), reduces surgical blood loss in patients who undergo transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH) with prostates ± 30 ml volume. The secondary objectives were to assess bleeding after TURP and postoperative complications like clot retention, blood transfusions, urinary tract infection (UTI), incontinence and acute urinary retention (AUR) following TURP. Two hundred and thirteen men aged 52-85 years (mean 67) with prostate volume of ± 30 ml were recruited from 23 centers across six countries. Two hundred and two had TURP and 197 completed the study. They were randomized to three groups: Group I receiving placebo for four weeks preoperatively and two weeks postoperatively, Group II receiving placebo for two weeks followed by dutasteride 0.5 mg for two weeks preoperatively and two weeks of dutasteride 0.5 mg daily among the treatment groups. Hemoglobin loss after TURP was about a third of the total surgical blood loss. one to three per cent of the patients in each group received blood transfusions. Clot retention occurred in 6-11% of the patients, AUR in 11-17%, UTI in 20-31% and urinary incontinence in 14-15% of the patients over 14 weeks, but there was no statistically significant differences among groups. Treatment with dutasteride did not alter the MVD in the prostatic urethra or in regions of nodular hyperplasia. The drug reduced the serum concentration of DHT by 86-89% ( P<0.001), while increasing serum testosterone level by 13-15% before treatment. Dutasteride also reduced the intraprostatic concentration of DHT by 10 times compared with placebo. No adverse events that were considered to be drug-related were recorded.
ACCESSION #
26156341

 

Related Articles

  • How should new treatments for benign prostatic hyperplasia be assessed? Kirk, David // BMJ: British Medical Journal (International Edition);5/15/93, Vol. 306 Issue 6888, p1283 

    Focuses on methods in assessing treatments for prostatic hyperplasia. Benefit of transurethral prostatectomy; Treatment for benign prostatic hyperplasia; Symptoms of benign prostatic hyperplasia.

  • Transurethral microwave treatment for benign prostatic hypertrophy: a randomised controlled clinical trial. Bdesha, A.S.; Bunce, C.J.; Kelleher, J.P.; Snell, M.E.; Vukusic, J.; Witherow, R.O'N. // BMJ: British Medical Journal (International Edition);5/15/93, Vol. 306 Issue 6888, p1293 

    Examines efficacy of transurethral microwave treatment for benign prostatic hypertrophy. Assessment on side-effect of treatment; Comparison between microwave treatment and sham treatment; Impact of urine volume reduction on treatment.

  • Holmium laser resection has slight edge over TURP. Tennant, Scott // Urology Times;Aug2000, Vol. 28 Issue 8, p6 

    Focuses on the efficacy of Holmium laser resection for treatment of benign prostatic hyperplasia in New Zealand. Comparison between transurethral resection of the prostate and laser resection; Possible complications of the process; Role of Holmium laser enucleation in improving Holmium laser...

  • Secondary hemorrhage after bipolar transurethral resection and vaporization of prostate. Chi-Hang Yee; Joseph Hon-Ming Wong; Peter Ka-Fung Chiu; Jeremy Yuen-Chun Teoh; Chi-Kwok Chan; Eddie Shu-Yin Chan; See-Ming Hou; Chi-Fai Ng // Urology Annals;Oct2016, Vol. 8 Issue 4, p458 

    Introduction: We evaluated the factors associated with secondary hemorrhage after bipolar transurethral resection of prostate (TURP) and vaporization of prostate. Materials and Methods: The perioperative data of patients undergoing endoscopic surgery for benign prostatic hyperplasia (BPH) were...

  • Glycine.  // Reactions Weekly;9/28/2013, Issue 1471, p26 

    The article presents a case study of a 78-year-old man who suffered from transurethral resection of prostate (TURP) syndrome due to use of glycine in surgery for prostatic hypertrophy.

  • The Effect of Modified TURP (M-TURP) in Intra and Postoperative Complications. Ali Asghar Ketabchi; Mahsa Ketabchi; Mohsen Barkam // Nephro-Urology Monthly;Jul2013, Vol. 5 Issue 3, p758 

    Background: Transurethral resection of the prostate (TURP) is the most common surgical treatment for benign prostatic hyperplasia. Objectives: The aim of the present study was to compare the conventional bipolar transurethral resection of prostate (TURP) with a modified transurethral resection...

  • Comparison of standard transurethral resection and holmium laser enucleation of prostate for managing benign prostatic hyperplasia: Our initial experience. Kar, Chandrakata; Yadav, S. S.; Mathur, R.; Yadav, R. G.; Sharma, K. K.; Sadasukhi, T. C. // Indian Journal of Urology;Supplement1, Vol. 24, pS18 

    Aim: To compare the safety and efficacy of an alternative for surgically treating symptomatic benign prostatic hyperplasia (BPH), i.e. holmium laser enucleation of prostate (HOLEP), with transurethral resection of prostate (TURP), the standard surgical therapy. Materials and Methods Methods: We...

  • A Modified Technique of Simple Suprapubic Prostatectomy. Moslemi, Mohammad Kazem; Zadeh, Mehdi Abedin // Urology Journal;Nov2010, Vol. 7 Issue 1, p51 

    Introduction: Open prostatectomy is the conventional surgical treatment of benign prostatic hyperplasia. The major early complication of this procedure is bleeding. We introduce a technique of prostatectomy in order to prevent significant bleeding, reduce morbidity, and shorten convalescence and...

  • New prostate microwave therapy is rapid, safe, and effective, but it's not for everyone.  // Modern Medicine;Jan97, Vol. 65 Issue 1, p14 

    Reports on the use of the Transurethral Microwave Thermotherapy (TUMT) as a non-surgical treatment option for benign prostatic hyperplasia (BPH). Elimination of excess prostatic cells via microwave heat; Safety and efficacy; Candidates for TUMT; Side effects; Availability; Reimbursement; Study...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics